# VectorY Therapeutics funding rounds and investors

As of 11 Nov 2026, VectorY Therapeutics has raised $82.9M across 1 verified round on record (amounts in other currencies converted to USD); latest: €74.5 million ($83.5 million) funding round, announced 11 Nov 2026.

A clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases

Headquarters: Amsterdam, The Netherlands  
Page: https://fireround.dev/companies/vectory-therapeutics

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-11 | Funding round | €74.5 million ($83.5 million) | not stated | ALS Investment Fund, Angelini Ventures, BioGeneration Ventures, Eli Lilly, EQT Life Sciences, European Investment Bank (EIB), Forbion, Insight Partners, Invest-NL, MRL Ventures Fund | [businesswire.com](https://www.businesswire.com/news/home/20261111459710/en/VectorY-Therapeutics-Raises-%E2%82%AC74.5-Million-%2483.5-Million-to-Advance-Clinical-and-Preclinical-Neurodegenerative-Disease-Pipeline), [thepharmaletter.com](https://www.thepharmaletter.com/biotech-news/vectory-raises-74-5-million-euros-to-take-tdp-43-als-therapy-through-phase-i-ii-readout) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.